

**What is claimed is:**

1. A method for inhibiting platelet aggregation in a mammal including human, comprising administering to the mammal including human an effective amount of adenosine.
2. A method for inhibiting thrombosis in a mammal including human, comprising administering to the mammal including human an effective amount of adenosine.
3. A method for preventing and treating thromboembolic disorders in a mammal including human, comprising administering to the mammal including human an effective amount of adenosine.
4. A method according to claim 3, wherein the thromboembolic disorders are selected from the group consisting of atherosclerosis and arteriosclerosis, acute myocardial infarction, angina, transient ischemic attacks and strokes, peripheral vascular diseases, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.
5. A method according to any one of claims 1 to 4, comprising administering to the mammal including human an effective amount of adenosine in association with an antithrombotic.
6. A method according to claim 5, wherein the antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, LMW heparin, ticlopidine, hirudin, and thromboxane A<sub>2</sub> synthase inhibitors or receptor antagonists.
7. An *in vitro* method for detecting the presence of gpIIb/IIIa in a sample suspected thereof, comprising contacting gpIIb/IIIa with adenosine.
8. Use of adenosine for inhibiting platelet aggregation in a mammal including human.
9. Use of adenosine as an antithrombotic.
10. A pharmaceutical composition for inhibiting platelet aggregation in a mammal including human, comprising an effective amount of adenosine and a

pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition for inhibiting thrombosis in a mammal including human, comprising an effective amount of adenosine and a  
5 pharmaceutically acceptable carrier or diluent.

12. A pharmaceutical composition for treating thromboembolic disorders in a mammal including human, comprising an effective amount of adenosine and a  
10 pharmaceutically acceptable carrier or diluent.

13. A pharmaceutical composition according to claim 12, wherein the thromboembolic disorders are selected from the group consisting of atherosclerosis and arteriosclerosis, acute myocardial infarction, angina, transient ischemic attacks and strokes, peripheral vascular diseases, arterial thrombosis,  
15 preeclampsia, embolism and carotid endarterectomy.

14. A pharmaceutical composition according to any one of claims 10 to 13, further comprising an antithrombotic.

15. A pharmaceutical composition according to claim 14, wherein the antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, LMW heparin, ticlopidine, hirudin, and thromboxane A<sub>2</sub> synthase inhibitors or receptor antagonists.

16. A kit for inhibiting platelet aggregation and thrombosis in a mammal including human, comprising a first container containing adenosine and a second container containing a pharmaceutically acceptable carrier or diluent.

17. A kit for inhibiting platelet aggregation and thrombosis in a mammal including human, comprising a first container containing adenosine, a second container containing an antithrombotic, and a third container containing a  
30 pharmaceutically acceptable carrier or diluent.

18. A kit according to claim 17, wherein the antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, LMW heparin, ticlopidine,  
35 hirudin, and thromboxane A<sub>2</sub> synthase inhibitors or receptor antagonists.